Affiliation:
1. School of Bioengineering Sciences and Research, MIT Arts, Design and Technology University, Pune, 412201, India
Abstract
Abstract:
Cancer ranks as the second leading cause of mortality in high-income countries, underscoring
the critical need for effective therapeutic strategies. One prominent approach, chemotherapy,
is widely employed for treating solid tumors. However, the significant adverse effects associated
with chemotherapy, notably myeloablation and osteonecrosis, impart considerable challenges
by compromising immune function and diminishing patients' quality of life. Furthermore, the
emergence of chemotherapy resistance poses a formidable hurdle in achieving successful cancer
treatment outcomes. In this context, the focus is on exploring alternative approaches to enhance
the efficacy of cancer treatment and mitigate its adverse consequences. Among these approaches,
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), two n-3 polyunsaturated fatty
acids (PUFAs), have garnered substantial interest. These PUFAs exhibit the potential to influence
membrane lipid composition and modulate critical gene expressions associated with cancer, such
as Bcl-2, PI3K, NF-κB, and phosphorylated Akt, thereby potentially reducing cancer risk. Moreover,
emerging evidence highlights their ability to augment chemotherapy efficacy, particularly in
drug-resistant cancer cells. Importantly, both preclinical and clinical investigations have provided
compelling evidence supporting the protective effects of n-3 PUFAs on healthy cells. Leveraging
these findings, there has been growing attention on the exploration of n-3 PUFAs as adjuvants to
chemotherapy. This strategic approach holds promise in mitigating the adverse effects linked to
chemotherapy, notably myeloablation and osteonecrosis, while simultaneously enhancing its effectiveness
in combating cancer. This comprehensive review delves into the multifaceted attributes
of n-3 PUFAs, encompassing their cytotoxic properties, potential as chemopreventive agents, and
their prospective role in ameliorating the adverse effects commonly associated with chemotherapy,
with a particular emphasis on myeloablation and osteonecrosis. By elucidating the intricate interplay
between n-3 PUFAs and cancer treatment paradigms, this review contributes to the expanding
body of knowledge aimed at refining cancer therapeutic strategies and enhancing patient outcomes.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,General Medicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献